Show simple item record

dc.contributor.authorCummins, Timothy
dc.date2022-08-11T08:08:07.000
dc.date.accessioned2022-08-23T15:43:13Z
dc.date.available2022-08-23T15:43:13Z
dc.date.issued2011-08-12
dc.date.submitted2017-08-16
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27037
dc.description.abstractPipeline PredictorRx™ evaluates new drugs, expected to have a significant clinical or financial impact when approved by the FDA, and compares them to current therapies. This UMass Medical School model, entirely independent of drug company interests, goes beyond detailing pharmacy outcomes for pipeline drugs — we also examine the potential for avoiding hospitalization and other medical costs.
dc.language.isoen_US
dc.subjectPipeline PredictorRx™
dc.subjectdrug evaluation
dc.subjectdrug impact
dc.subjectpipeline drugs
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectPharmacy and Pharmaceutical Sciences
dc.titlePipeline Predictor Rx
dc.typeReport
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1053&context=commed_pubs&unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/commed_pubs/44
dc.identifier.contextkey10608357
refterms.dateFOA2022-08-23T15:43:13Z
html.description.abstract<p>Pipeline PredictorRx™ evaluates new drugs, expected to have a significant clinical or financial impact when approved by the FDA, and compares them to current therapies.</p> <p>This UMass Medical School model, entirely independent of drug company interests, goes beyond detailing pharmacy outcomes for pipeline drugs — we also examine the potential for avoiding hospitalization and other medical costs.</p>
dc.identifier.submissionpathcommed_pubs/44
dc.contributor.departmentCommonwealth Medicine, Clinical Pharmacy Services


Files in this item

Thumbnail
Name:
PipelinePredictorRx.pdf
Size:
628.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record